Skip to main content
Erschienen in: Annals of Surgical Oncology 6/2019

21.02.2019 | Pancreatic Tumors

The Prognostic Relevance of the New 8th Edition of the Union for International Cancer Control Classification of TNM Staging for Ampulla of Vater Carcinoma

verfasst von: Taisuke Imamura, MD, PhD, Yusuke Yamamoto, MD, PhD, Teiichi Sugiura, MD, PhD, Yukiyasu Okamura, MD, PhD, Takaaki Ito, MD, PhD, Ryo Ashida, MD, PhD, Katsuhisa Ohgi, MD, Katsuhiko Uesaka, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Objective

The aim of this study was to investigate the clinical relevance of the 8th edition of the Union for International Cancer Control classification of TNM staging for ampulla of Vater carcinoma (AC).

Methods

A total of 104 consecutive patients who underwent macroscopic curative resection for AC between January 2002 and September 2017 were investigated.

Results

Significant differences in recurrence-free survival (RFS) were found between T1a and T1b (p = 0.0030), but not between T1b and T2 (p = 0.9319), T2 and T3a (p = 0.0732), or T3a and T3b (p = 0.2118). The prognostic impact of the depth of duodenal invasion and pancreatic invasion, which define the T category, were evaluated. With regard to duodenal invasion, significant differences in RFS were found between the negative and submucosa classifications (p = 0.0012) and the muscularis propria and serosa classifications (p = 0.0131), but not between the submucosa and muscularis propria classifications (p = 0.6390). With regard to pancreatic invasion, significant differences in RFS were found between the negative and ≤ 0.5 cm classifications (p = 0.0001), and ≤ 0.5 cm and > 0.5 cm classifications (p = 0.0062). A Cox proportional hazard analysis for RFS revealed that duodenal invasion (submucosa or muscularis propria/negative, hazard ratio [HR] 5.08; serosa/negative, HR 7.42), and pancreatic invasion (≤ 0.5 cm/negative, HR 8.23; > 0.5 cm/negative, HR 9.81) were independent prognostic factors. An alternative new T category was proposed, based on the HRs, as follows: T1, tumor limited to the ampulla of Vater or sphincter of Oddi; T2, duodenal invasion (submucosa or muscularis propria); T3, pancreatic invasion (≤ 0.5 cm) or duodenal invasion (serosa); and T4, pancreatic invasion (> 0.5 cm). This alternative T category can well classify each subgroup with prognostic differences.

Conclusions

Reconsideration of the T category based on the prognostic impact of TNM factors, including the depth of duodenal and pancreatic invasion, are required in the 8th edition T category.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Riall TS, Cameron JL, Lillemoe KD, et al. Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. Surgery. 2006;140(5):764–772.CrossRefPubMed Riall TS, Cameron JL, Lillemoe KD, et al. Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. Surgery. 2006;140(5):764–772.CrossRefPubMed
2.
Zurück zum Zitat Bettschart V, Rahman MQ, Engelken FJ, Madhavan KK, Parks RW, Garden OJ. Presentation, treatment and outcome in patients with ampullary tumours. Br J Surg. 2004;91(12):1600–1607.CrossRefPubMed Bettschart V, Rahman MQ, Engelken FJ, Madhavan KK, Parks RW, Garden OJ. Presentation, treatment and outcome in patients with ampullary tumours. Br J Surg. 2004;91(12):1600–1607.CrossRefPubMed
3.
Zurück zum Zitat Inoue Y, Hayashi M, Hirokawa F, Egashira Y, Tanigawa N. Clinicopathological and operative factors for prognosis of carcinoma of the ampulla of vater. Hepato-Gastroenterology. 2012;59(117):1573–1576. Inoue Y, Hayashi M, Hirokawa F, Egashira Y, Tanigawa N. Clinicopathological and operative factors for prognosis of carcinoma of the ampulla of vater. Hepato-Gastroenterology. 2012;59(117):1573–1576.
4.
Zurück zum Zitat Jemal A, Siegel R, Ward E, et al. (2008) Cancer statistics. Cancer J Clin. 2008;58(2):71–96.CrossRef Jemal A, Siegel R, Ward E, et al. (2008) Cancer statistics. Cancer J Clin. 2008;58(2):71–96.CrossRef
5.
Zurück zum Zitat Albores-Saavedra J, Schwartz AM, Batich K, Henson DE. Cancers of the ampulla of vater: demographics, morphology, and survival based on 5625 cases from the SEER program. J Surg Oncol. 2009;100(7):598–605.CrossRefPubMed Albores-Saavedra J, Schwartz AM, Batich K, Henson DE. Cancers of the ampulla of vater: demographics, morphology, and survival based on 5625 cases from the SEER program. J Surg Oncol. 2009;100(7):598–605.CrossRefPubMed
6.
Zurück zum Zitat Kohga A, Yamamoto Y, Sano S, et al. Surgical strategy for T1 duodenal or ampullary carcinoma according to the depth of tumor invasion. Anticancer Res. 2017;37(9):5277–5283.PubMed Kohga A, Yamamoto Y, Sano S, et al. Surgical strategy for T1 duodenal or ampullary carcinoma according to the depth of tumor invasion. Anticancer Res. 2017;37(9):5277–5283.PubMed
8.
Zurück zum Zitat You D, Heo J, Choi S, Choi D, Jang KT. Pathologic T1 subclassification of ampullary carcinoma with perisphincteric or duodenal submucosal invasion: Is it T1b? Arch Pathol Lab Med. 2014;138(8):1072–1076.CrossRefPubMed You D, Heo J, Choi S, Choi D, Jang KT. Pathologic T1 subclassification of ampullary carcinoma with perisphincteric or duodenal submucosal invasion: Is it T1b? Arch Pathol Lab Med. 2014;138(8):1072–1076.CrossRefPubMed
9.
Zurück zum Zitat Kim SJ, An S, Kang HJ, et al. Validation of the eighth edition of the American Joint Committee on Cancer staging system for ampulla of Vater cancer. Surgery. 2018;163(5):1017–1079. Kim SJ, An S, Kang HJ, et al. Validation of the eighth edition of the American Joint Committee on Cancer staging system for ampulla of Vater cancer. Surgery. 2018;163(5):1017–1079.
10.
Zurück zum Zitat Alessandrino F, Ivanovic AM, Yee EU, Radulovic D, Souza D, Mortele KJ. MDCT and MRI of the ampulla of Vater. Abdom Imaging. 2015;40(8):3274–3291.CrossRefPubMed Alessandrino F, Ivanovic AM, Yee EU, Radulovic D, Souza D, Mortele KJ. MDCT and MRI of the ampulla of Vater. Abdom Imaging. 2015;40(8):3274–3291.CrossRefPubMed
11.
Zurück zum Zitat Chan C, Herrera MF, de la Garza L, et al. Clinical behavior and prognostic factors of periampullary adenocarcinoma. Ann Surg. 1995;222(5):632–637.CrossRefPubMedCentralPubMed Chan C, Herrera MF, de la Garza L, et al. Clinical behavior and prognostic factors of periampullary adenocarcinoma. Ann Surg. 1995;222(5):632–637.CrossRefPubMedCentralPubMed
12.
Zurück zum Zitat Adsay NV, Bagci P, Tajiri T, et al. Pathologic staging of pancreatic, ampullary, biliary, and gallbladder cancers: pitfalls and practical limitations of the current AJCC/UICC TNM staging system and opportunities for improvement. Semin Diagn Pathol. 2012;29(3):127–141.CrossRefPubMed Adsay NV, Bagci P, Tajiri T, et al. Pathologic staging of pancreatic, ampullary, biliary, and gallbladder cancers: pitfalls and practical limitations of the current AJCC/UICC TNM staging system and opportunities for improvement. Semin Diagn Pathol. 2012;29(3):127–141.CrossRefPubMed
13.
Zurück zum Zitat Sakata J, Shirai Y, Wakai T, et al. Number of positive lymph nodes independently affects long-term survival after resection in patients with ampullary carcinoma. Eur J Surg Oncol. 2007;33(3):346–351.CrossRefPubMed Sakata J, Shirai Y, Wakai T, et al. Number of positive lymph nodes independently affects long-term survival after resection in patients with ampullary carcinoma. Eur J Surg Oncol. 2007;33(3):346–351.CrossRefPubMed
14.
Zurück zum Zitat Kanai M, Hatano E, Kobayashi S, et al. A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002). Cancer Chemother Pharmacol. 2015;75(2):293–300.CrossRefPubMed Kanai M, Hatano E, Kobayashi S, et al. A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002). Cancer Chemother Pharmacol. 2015;75(2):293–300.CrossRefPubMed
15.
Zurück zum Zitat Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–1281.CrossRefPubMed Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–1281.CrossRefPubMed
16.
Zurück zum Zitat Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010;103(4):469–474.CrossRefPubMedCentralPubMed Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010;103(4):469–474.CrossRefPubMedCentralPubMed
Metadaten
Titel
The Prognostic Relevance of the New 8th Edition of the Union for International Cancer Control Classification of TNM Staging for Ampulla of Vater Carcinoma
verfasst von
Taisuke Imamura, MD, PhD
Yusuke Yamamoto, MD, PhD
Teiichi Sugiura, MD, PhD
Yukiyasu Okamura, MD, PhD
Takaaki Ito, MD, PhD
Ryo Ashida, MD, PhD
Katsuhisa Ohgi, MD
Katsuhiko Uesaka, MD, PhD
Publikationsdatum
21.02.2019
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 6/2019
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07238-6

Weitere Artikel der Ausgabe 6/2019

Annals of Surgical Oncology 6/2019 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.